159
invite is a new Chinese single-dose viral vector vaccine, already authorized as an emergency in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, Indonesia and Malaysia. The results of the phase 3 control study have just been published on The Lancet and speak of an efficacy of 57.5% against symptomatic infection and 91.7% against severe forms, starting 28 days after vaccination.
.